Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express programmed death ligand 1 (PD-L1). METHODS: In this open-label, phase 3 trial, we randomly assigned 305 patients who had previously untreated advanced NSCLC with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation of the epidermal growth factor receptor gene or translocation of the anaplastic lymphoma kinase gene to receive either pembrolizumab (at a fixed dose of 200 mg every 3 weeks) or the investigator's choice of platinum-based chemotherapy. Crossover from the chemotherapy group to the pembrolizumab group was permitted in the event of disease progression. The primary end point, progression-free survival, was assessed by means of blinded, independent, central radiologic review. Secondary end points were overall survival, objective response rate, and safety. RESULTS: Median progression-free survival was 10.3 months (95% confidence interval [CI], 6.7 to not reached) in the pembrolizumab group versus 6.0 months (95% CI, 4.2 to 6.2) in the chemotherapy group (hazard ratio for disease progression or death, 0.50; 95% CI, 0.37 to 0.68; P<0.001). The estimated rate of overall survival at 6 months was 80.2% in the pembrolizumab group versus 72.4% in the chemotherapy group (hazard ratio for death, 0.60; 95% CI, 0.41 to 0.89; P=0.005). The response rate was higher in the pembrolizumab group than in the chemotherapy group (44.8% vs. 27.8%), the median duration of response was longer (not reached [range, 1.9+ to 14.5+ months] vs. 6.3 months [range, 2.1+ to 12.6+]), and treatment-related adverse events of any grade were less frequent (occurring in 73.4% vs. 90.0% of patients), as were grade 3, 4, or 5 treatment-related adverse events (26.6% vs. 53.3%). CONCLUSIONS: In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival and with fewer adverse events than was platinum-based chemotherapy. (Funded by Merck; KEYNOTE-024 ClinicalTrials.gov number, NCT02142738 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, ICIs are also associated with frequent and potentially organ- or life-threatening immune-related adverse events (irAEs), which generally mimic autoimmune or inflammatory conditions”
From Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database (2020) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“indeed, up to 90% of patients treated with ipilimumab and up to 70% of those treated with PD-1/PD-L1 antibodies experience at least one irAE).3,4”
From Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database (2020) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Initial trials on anti-PD-1 and anti-PD-L1 inhibitors reported a significant association between pre-treatment intratumoral PD-L1 expression and response to treatment in a variety of tumor types including melanoma and NSCLC”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Reck et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At present, antibodies blocking PD-1 or its ligand PD-L1 have been approved to treat various solid and hematologic malignancies (Table 1) [7–12].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Response rates range from 15 to 30% (in most solid tumors) to 45–60% (in melanoma and MSI-H tumors).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [6]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationImproved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Self-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Research works printed but not linked: 1
- Xiao HQ, 2016, Onco Targets Ther, 9, 1471
Cited by
Items 901–1,000 of 1,054
Subphenotypes in acute kidney injury: a narrative review
Vaara, S. T., Bhatraju, P. K., Stanski, N. L., McMahon, B. A., Liu, K. D., Joannidis, M., & Bagshaw, S. M. (2022) · Critical Care · doi:10.1186/s13054-022-04121-x · Cited by 113
Eng, L., Sutradhar, R., Niu, Y., Liu, N., Liu, Y., Kaliwal, Y., Powis, M. L., Liu, G., Peppercorn, J. M., Bedard, P. L., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00074 · Cited by 105
Adams, D. L., Adams, D. K., He, J., Kalhor, N., Zhang, M., Xu, T., Gao, H., Reuben, J. M., Qiao, Y., Komaki, R. R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0802 · Cited by 113
Munari, E., Zamboni, G., Marconi, M., Sommaggio, M., Brunelli, M., Martignoni, G., Netto, G. J., Moretta, F., Mingari, M. C., Salgarello, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21485 · Cited by 112
Zhou, M., Chen, X., Zhang, H., Xia, L., Tong, X., Zou, L., Hao, R., Pan, J., Zhao, X. Q., Chen, D., et al. (2019) · 癌症:英文版 · doi:10.1186/s40880-019-0383-7 · Cited by 112
Targeted Therapies and Biomarkers in Small Cell Lung Cancer
Taniguchi, H., Sen, T., & Rudin, C. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00741 · Cited by 112
Boyero, L., Sánchez-Gastaldo, A., Alonso, M. D., Noguera-Uclés, J. F., Molina‐Pinelo, S., & Bernabé, R. (2020) · Cancers · doi:10.3390/cancers12123729 · Cited by 112
Shimada, Y., Matsubayashi, J., Kudo, Y., Maehara, S., Takeuchi, S., Hagiwara, M., Kakihana, M., Ohira, T., Nagao, T., & Ikeda, N. (2021) · Scientific Reports · doi:10.1038/s41598-021-87575-3 · Cited by 112
Immunotherapy in endometrial cancer: rationale, practice and perspectives
Cao, W., Ma, X., Fischer, J. V., Sun, C., Kong, B., & Zhang, Q. H. (2021) · Biomarker Research · doi:10.1186/s40364-021-00301-z · Cited by 112
Li, T., Liu, T., Zhu, W., Xie, S., Zhao, Z., Feng, B., Guo, H., & Yang, R. (2021) · Clinical Medicine Insights Oncology · doi:10.1177/11795549211035540 · Cited by 114
Alessi, J. V., Ricciuti, B., Alden, S. L., Bertram, A. A., Lin, J. J., Sakhi, M., Nishino, M., Vaz, V. R., Lindsay, J. R., Turner, M. M., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003536 · Cited by 112
Pérol, M., Felip, E., Dafni, U. G., Polito, L., Pal, N., Tsourti, Z., Ton, T. G. N., Merritt, D., Morris, S., Stahel, R. A., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.02.008 · Cited by 113
IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy
Johnson, D., Patel, A. B., Uemura, M. I., Trinh, V. A., Jackson, N., Zobniw, C. M., Tetzlaff, M. T., Hwu, P., Curry, J. L., & Diab, A. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0682 · Cited by 111
Russo, A., Franchina, T., Ricciardi, G. R. R., Battaglia, A., Scimone, A., Berenato, R., Giordano, A., & Adamo, V. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26609 · Cited by 111
Heeke, S., & Hofman, P. M. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.08.04 · Cited by 111
Zhou, Y., Chen, C., Zhang, X., Fu, S., Xue, C., Ma, Y., Fang, W., Yang, Y., Hou, X., Huang, Y., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0477-9 · Cited by 111
Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors
Chong, C. R., Park, V. J., Cohen, B., Postow, M. A., Wolchok, J. D., & Kamboj, M. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz202 · Cited by 111
The biological functions and clinical applications of exosomes in lung cancer
Chen, R., Xu, X., Qian, Z., Zhang, C., Niu, Y., Wang, Z., Sun, J., Zhang, X., & Yu, Y. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03233-y · Cited by 111
Gaudreau, P.-O., Negrao, M. V., Mitchell, K. G., Reuben, A., Corsini, E. M., Li, J., Karpinets, T. V., Wang, Q., Diao, L., Wang, J., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.09.027 · Cited by 111
Weiss, S. A., Djureinovic, D., Jessel, S., Krykbaeva, I., Zhang, L., Jilaveanu, L., Ralabate, A., Johnson, B., Levit, N. S., Anderson, G., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0903 · Cited by 102
Interleukin-10-regulated tumour tolerance in non-small cell lung cancer
Vahl, J. M., Friedrich, J., Mittler, S., Trump, S., Heim, L., Kachler, K., Balabko, L., Fuhrich, N., Geppert, C.-I., Trufa, D. I., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.336 · Cited by 105
Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy
Torphy, R., Schulick, R., & Zhu, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122642 · Cited by 97
Carlino, M. S., Long, G. V., Schadendorf, D., Robert, C., Ribas, A., Richtig, E., Nyakas, M., Caglevic, C., Tarhini, A., Blank, C. U., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.06.034 · Cited by 110
Adeegbe, D. O., Liu, S., Hattersley, M. M., Bowden, M., Zhou, C. W., Li, S., Vlahos, R., Grondine, M. R., Dolgalev, I., Ivanova, E. V., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0077 · Cited by 110
Insinga, R. P., Vanness, D. J., Feliciano, J. L., Vandormael, K., Traoré, S., & Burke, T. A. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2018.1521416 · Cited by 112
Maity, A. M., Mick, R., Huang, A. C. C., George, S. M., Farwell, M. D., Lukens, J. N., Berman, A. T., Mitchell, T. C., Bauml, J., Schuchter, L. M., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0281-9 · Cited by 110
Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges
Kunimasa, K., & Goto, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020597 · Cited by 113
Suzuki, Y., Karayama, M., Uto, T., Fujii, M., Matsui, T., Asada, K., Kusagaya, H., Kato, M., Matsuda, H., Matsuura, S., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.04.002 · Cited by 111
Sha, C. M., Lehrer, E. J., Hwang, C., Trifiletti, D. M., Mackley, H. B., Drabick, J. J., & Zaorsky, N. G. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.07.035 · Cited by 110
Immunosuppressive Property of MSCs Mediated by Cell Surface Receptors
Liu, S., Liu, F., Zhou, Y. L., Jin, B., Sun, Q., & Guo, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01076 · Cited by 110
Marchi, P. D., Leal, L. F., da Silva, V. D., da Silva, E. C. A., de Lima, V. C. C., & Reis, R. M. (2021) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2020-206832 · Cited by 110
Liu, C., Yang, L., Xu, H., Zheng, S., Wang, Z., Wang, S., Yang, Y., Zhang, S., Feng, X., Sun, N., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02356-7 · Cited by 110
The Role of Immune Checkpoint Inhibitors in Cancer Therapy
Basudan, A. (2022) · Clinics and Practice · doi:10.3390/clinpract13010003 · Cited by 110
Davri, A. S., Birbas, E., Kanavos, T., Ntritsos, G., Γιαννακέας, Ν., Tzallas, A. T., & Batistatou, A. K. (2023) · Cancers · doi:10.3390/cancers15153981 · Cited by 110
Yu, Y., Ma, X., Zhang, Y., Zhang, Y., Ying, J., Zhang, W., Zhong, Q., Zhou, A., & Zeng, Y. (2019) · Journal of Cancer · doi:10.7150/jca.31755 · Cited by 110
Zhang, N., Jiang, J., Tang, S., & Sun, G. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106677 · Cited by 109
Wang, P., Ting-jian, W., Yang, Y., Yao, K., Li, Z., Li, Y. M., & Yan, C. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2844-2 · Cited by 109
Der prädiktive Wert der PD-L1-Diagnostik
Schildhaus, H. (2018) · Der Pathologe · doi:10.1007/s00292-018-0507-x · Cited by 109
Ouaknine Krief, J., Helly de Tauriers, P., Dumenil, C., Neveux, N., Dumoulin, J., Giraud, V., Labrune, S., Tisserand, J., Julie, C., Emile, J.-F., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0658-1 · Cited by 99
Sato, Y., Fu, Y., Liu, H., Lee, M. Y., & Shaw, M. H. (2021) · BMC Cancer · doi:10.1186/s12885-021-08974-3 · Cited by 109
Mountzios, G., Samantas, E., Senghas, K., Ζervas, Ε., Krisam, J., Samitas, Κ., Bozorgmehr, F., Kuon, J., Agelaki, S., Baka, S., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100254 · Cited by 109
Self-citationTargeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia
Yang, X., Ma, L., Zhang, X., Huang, L., & Wei, J. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00263-4 · Cited by 109
Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings
Wang, G. X., Kurra, V., Gainor, J. F., Sullivan, R. J., Flaherty, K. T., Lee, S. I., & Fintelmann, F. J. (2017) · Radiographics · doi:10.1148/rg.2017170085 · Cited by 108
Carretero-González, A., Lora, D., Ghanem, I., Zugazagoitia, J., Castellano, D., Sepúlveda-Sánchez, J. M., Lopez-Martin, J. A., Paz-Ares, L. G., & de Velasco, G. (2018) · Oncotarget · doi:10.18632/oncotarget.24283 · Cited by 108
Saigí, M., Alburquerque-Béjar, J. J., Leer, A. M., Pereira, C. A., Pros, E., Romero, O. A., Baixeras, N., Esteve‐Codina, A., Nadal, E., Brambilla, E. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0267 · Cited by 108
Yeong, J. P.-S., Lim, J. C. T., Lee, B. T. K., Li, H., Ong, C. C. H., Thike, A. A., Yeap, W. H., Yang, Y. L., Lim, A. Y. H., Tay, T. K. Y., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0499-y · Cited by 109
Chen, D., Menon, H., Verma, V., Guo, C., Ramapriyan, R., Barsoumian, H. B., Younes, A. I. A., Hu, Y. Y., Wasley, M. D., Cortez, M. A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000492 · Cited by 108
Patient-derived cell line, xenograft and organoid models in lung cancer therapy
Huo, K.-G., D’Arcangelo, E., & Tsao, M. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-154 · Cited by 108
Wu, Y.-L. L. C., Zhang, L., Fan, Y., Zhou, J., Zhang, L., Zhou, Q. H., Li, W., Hu, C., Chen, G., Zhang, X., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33399 · Cited by 108
Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance
Yang, M., Cui, M., Sun, Y., Liu, S., & Jiang, W. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01711-w · Cited by 110
Combining radiotherapy with immunotherapy: the past, the present and the future
Limbergen, E. J. V., Ruysscher, D. D., Pimentel, V. O., Marcus, D., Berbée, M., Hoeben, A., Rekers, N. H., Theys, J., Yaromina, A., Dubois, L. J., et al. (2017) · British Journal of Radiology · doi:10.1259/bjr.20170157 · Cited by 107
Shin, J., Chung, J.-H., Kim, S. H., Lee, K. S., Suh, K. J., Lee, J. Y., Kim, J.-W., Lee, J.-O., Kim, J.-W., Kim, Y.-J., et al. (2019) · Cancer Research and Treatment · doi:10.4143/crt.2018.537 · Cited by 101
Chen, Y., Liu, Q., Chen, Z., Wang, Y., Yang, W., Hu, Y., Han, W., Zeng, H., Ma, H., Dai, J., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1192-1 · Cited by 107
Shepard, M. J., Xu, Z., Donahue, J., Muttikkal, T. J. E., Cordeiro, D. P., Hansen, L., Mohammed, N., Gentzler, R. D., Larner, J. M., Fadul, C. E., et al. (2019) · Journal of neurosurgery · doi:10.3171/2019.4.jns19822 · Cited by 107
Zhai, X., Zhang, J., Tian, Y., Li, J., Wang, J., Guo, H., & Zhu, H. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0102 · Cited by 107
Yang, Y. A., Yang, J., Shen, L., Chen, J., Xia, L., Ni, B., Ge, L., Wang, Y., & Lü, S. (2021) · PubMed Central · Cited by 112
Jagieła, J., Bartnicki, P., & Rysz, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094618 · Cited by 107
Elkrief, A., Pidgeon, R., Vareki, S. M., Messaoudene, M., Castagner, B., & Routy, B. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01211-7 · Cited by 109
Verma, V., Simone, C. B., & Werner‐Wasik, M. (2017) · Cancers · doi:10.3390/cancers9090120 · Cited by 107
Petrelli, F., Ardito, R., Borgonovo, K., Lonati, V., Cabiddu, M., Ghilardi, M., & Barni, S. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.07.129 · Cited by 107
Marchetti, A., Barberis, M. C. P., Franco, R., Luca, G. D., Pace, M. V., Staibano, S., Volante, M., Buttitta, F., Guerini‐Rocco, E., Righi, L., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.07.031 · Cited by 106
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes
Sharma, G. G., Mota, I. A., Mologni, L., Patrucco, E., Gambacorti-Passerini, C. B., & Chiarle, R. (2018) · Cancers · doi:10.3390/cancers10030062 · Cited by 107
Treatment of Advanced Non–Small Cell Lung Cancer in 2018
Doroshow, D. B., & Herbst, R. S. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5190 · Cited by 106
Addeo, A., Banna, G. L., Metro, G., & Maïo, M. D. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00264 · Cited by 106
Ultrathin Metal-Organic-Layer Mediated Radiotherapy-Radiodynamic Therapy
Ni, K., Lan, G., Chan, C., Duan, X., Guo, N., Veroneau, S. S., Weichselbaum, R. R., & Lin, W. (2019) · Matter · doi:10.1016/j.matt.2019.06.007 · Cited by 106
Sidders, B. S., Zhang, P., Goodwin, K., O’Connor, G., Russell, D. L., Borodovsky, A., Armenia, J., McEwen, R. K., Linghu, B., Bendell, J. C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2183 · Cited by 107
Conquering lung cancer: current status and prospects for the future
Pirker, R. (2020) · Pulmonology · doi:10.1016/j.pulmoe.2020.02.005 · Cited by 106
Lamberti, G., Spurr, L. F., Li, Y., Ricciuti, B., Recondo, G., Umeton, R., Nishino, M., Sholl, L. M., Meyerson, M. L., Cherniack, A. D., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.017 · Cited by 98
Mansfield, A. S., Herbst, R. S., de Castro, G., Hui, R., Peled, N., Kim, D., Novello, S., Satouchi, M., Wu, Y.-L. L. C., Garon, E. B., et al. (2021) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2021.100205 · Cited by 106
Self-citationJiang, T., Wang, P., Zhang, J., Zhao, Y., Zhou, J., Fan, Y., Shu, Y., Liu, X., Zhang, H., He, J., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00751-9 · Cited by 107
Pulmonary Sarcomatoid Carcinoma: An Analysis of the National Cancer Data Base
Steuer, C. E., Behera, M., Liu, Y., Fu, C., Gillespie, T. W., Saba, N. F., Shin, D. M., Pillai, R. N., Pakkala, S., Owonikoko, T. K., et al. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.11.016 · Cited by 105
Initial Experience With Lung Cancer Resection After Treatment With T-Cell Checkpoint Inhibitors
Chaft, J. E., Hellmann, M. D., Velez, M. J., Travis, W. D., & Rusch, V. W. (2017) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2017.03.038 · Cited by 105
Lisberg, A. E., Tucker, D. A., Goldman, J. W., Wolf, B., Carroll, J., Hardy, A., Morris, K. K., Linares, P., Adame, C. R., Spiegel, M. L., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0063 · Cited by 105
Iivanainen, S., Ahvonen, J., Knuuttila, A., Tiainen, S., & Koivunen, J. P. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000531 · Cited by 106
Lai, A. Y., Sorrentino, J. A., Dragnev, K. H., Weiss, J., Owonikoko, T. K., Rytlewski, J. A., Hood, J. V. W., Zhao, Y., Malik, R. K., Strum, J. C., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000847 · Cited by 105
Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer
Liang, W., Cai, K., Chen, C., Chen, H., Chen, Q., Fu, J., Hu, J., Jiang, T., Jiao, W., Li, S., et al. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-2020-63 · Cited by 105
Li, R., Salehi‐Rad, R., Crosson, W. P., Momcilovic, M., Lim, R. J., Ong, S. L., Huang, Z. L., Zhang, T.-H., Abascal, J. W., Dumitras, C., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3564 · Cited by 105
A Checkpoint‐Regulatable Immune Niche Created by Injectable Hydrogel for Tumor Therapy
Li, Q., Zhao, Z., Qin, X., Zhang, M., Du, Q., Li, Z., & Luan, Y. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202104630 · Cited by 106
Menon, D. R., Li, Y., Yamauchi, T., Osborne, D. G., Vaddi, P. K., Wempe, M. F., Zhai, Z., & Fujita, M. (2021) · Pharmaceuticals · doi:10.3390/ph14111081 · Cited by 106
Dugage, M. R., Nassif, E. F., Italiano, A., & Bahleda, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.775761 · Cited by 106
Jaiyesimi, I. A., Leighl, N. B., Ismaila, N., Alluri, K., Florez, N., Gadgeel, S., Masters, G., Schenk, E. L., Schneider, B. J., Sequist, L., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02746 · Cited by 82
AJRCCM : 100-Y ear A nniversary . The Shifting Landscape for Lung Cancer: Past, Present, and Future
Vachani, A., Sequist, L. V. D., & Spira, A. E. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201702-0433ci · Cited by 104
Pembrolizumab as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer
Reck, M. (2017) · Immunotherapy · doi:10.2217/imt-2017-0121 · Cited by 104
Self-citationFukui, T., Okuma, Y., Nakahara, Y., Otani, S., Igawa, S., Katagiri, M., Mitsufuji, H., Kubota, M., Hiyoshi, Y., Ishihara, M., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.04.021 · Cited by 105
EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions
Sasaki, S., Nishikawa, J., Sakai, K., Iizasa, H., Yoshiyama, H., Yanagihara, M., Shuto, T., Shimokuri, K., Kanda, T., Suehiro, Y., et al. (2018) · Gastric Cancer · doi:10.1007/s10120-018-0880-4 · Cited by 104
Hendriks, L. E. L., Rouleau, É., & Besse, B. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.09.22 · Cited by 104
Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy
Althammer, S., Tan, T. H., Spitzmüller, A., Rognoni, L., Wiestler, T., Herz, T., Widmaier, M., Rebelatto, M. C., Kaplon, H., Damotte, D., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0589-x · Cited by 99
Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges
Pavan, A., Attili, I., Pasello, G., Guarneri, V., Conte, P., & Bonanno, L. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0690-1 · Cited by 104
Systematic construction and validation of an immune prognostic model for lung adenocarcinoma
Luo, C., Lei, M., Zhang, Y., Zhang, Q., Li, L., Lian, J., Liu, S., Wang, L., Pi, G., & Zhang, Y. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14719 · Cited by 104
Aggarwal, C., Thompson, J. C., Chien, A. L., Quinn, K. J., Hwang, W.-T., Black, T. A., Yee, S. S., Christensen, T. E., LaRiviere, M. J., Silva, B. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3663 · Cited by 102
Polverari, G., Ceci, F., Bertaglia, V., Reale, M. L., Rampado, O., Gallio, E., Passera, R., Liberini, V., Scapoli, P., Arena, V., et al. (2020) · Cancers · doi:10.3390/cancers12051163 · Cited by 104
Soundararajan, R., Fradette, J., Konen, J., Moulder, S., Zhang, X., Gibbons, D., Varadarajan, N., Wistuba, I., Tripathy, D., Bernatchez, C., et al. (2019) · Cancers · doi:10.3390/cancers11050714 · Cited by 103
Goyal, A., Bauer, J., Hey, J., Papageorgiou, D. N., Stepanova, E., Daskalakis, M., Scheid, J., Dubbelaar, M., Klimovich, B., Schwarz, D., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42417-w · Cited by 102
Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC
Welsh, J. W., Heymach, J. V., Guo, C., Menon, H., Klein, K., Cushman, T. R., Verma, V., Hess, K. R., Shroff, G., Tang, C., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.08.022 · Cited by 101
Iwatate, Y., Hoshino, I., Yokota, H., Ishige, F., Itami, M., Mori, Y., Chiba, S., Arimitsu, H., Yanagibashi, H., Nagase, H., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0997-1 · Cited by 101
Takada, K., Shimokawa, M., Takamori, S., Shimamatsu, S., Hirai, F., Tagawa, T., Okamoto, T., Hamatake, M., Tsuchiya‐Kawano, Y., Otsubo, K., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33557 · Cited by 100
Gastrointestinal toxicity of immune checkpoint inhibitors: From mechanisms to management
Samaan, M. A., Pavlidis, P., Papa, S., Powell, N., & Irving, P. M. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2018.14 · Cited by 100
Marur, S., Singh, H., Mishra-Kalyani, P., Larkins, E., Keegan, P., Sridhara, R., Blumenthal, G. M., & Pazdur, R. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.08.007 · Cited by 100
Luo, F., Lu, F.-T., Cao, J.-X., Ma, W.-J., Xia, Z.-F., Zhan, J.-H., Zeng, K.-M., Huang, Y., Zhao, H.-Y., & Zhang, L. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.01.027 · Cited by 95
Aging, immune senescence, and immunotherapy: a comprehensive review
Elias, R., Hartshorn, K., Rahma, O., Lin, N., & Snyder-Cappione, J. E. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.08.006 · Cited by 96
Metadata
- Authors
- Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., O’Brien, M., Rao, S., Hotta, K., Leiby, M. A., Lubiniecki, G. M., Shentu, Y., Rangwala, R., & Brahmer, J. R.
- Affiliations
- The University of Sydney (AU)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-11-10
- Volume
- 375
- Issue
- 19
- Pages
- 1823-1833
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2527905628
- Cited by
- 10,089
- References
- 54
- Citations by year
- 2026: 584 · 2025: 750 · 2024: 913 · 2023: 1012 · 2022: 1108 · 2021: 1321 · 2020: 1324 · 2019: 1154 · 2018: 1132 · 2017: 724 · 2016: 46
- FWCI
- 548.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- QUT ePrints (Queensland University of Technology) (submittedVersion)
- Funders
- Health Research Board (ICORG-2016-1)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- pembrolizumab, PD-L1-positive non-small cell lung cancer, PD-1 inhibitors, immune checkpoint inhibitors, platinum-based chemotherapy, progression-free survival, overall survival, objective response rate, treatment-related adverse events, EGFR wild-type, immunotherapy versus chemotherapy, duration of response
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Survival Analysis, Platinum Compounds, Intention to Treat Analysis, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.